Serum proteomic profiling in patients with drug-induced liver injury

L. N. Bell, Raj Vuppalanchi, P. B. Watkins, H. L. Bonkovsky, J. Serrano, R. J. Fontana, Mu Wang, J. Rochon, Naga Chalasani

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is difficult to predict, diagnose and treat. Aim To describe the global serum proteome of patients with DILI and controls. Methods A label-free, mass spectrometry-based quantitative proteomic approach was used to explore protein expression in serum samples from 74 DILI patients (collected within 14 days of DILI onset) and 40 controls. A longitudinal analysis was conducted in a subset of 21 DILI patients with available 6-month follow-up serum samples. Results Comparison of DILI patients based on pattern, severity and causality assessment of liver injury revealed many differentially expressed priority 1 proteins among groups. Expression of fumarylacetoacetase was correlated with alanine aminotransferase (ALT; r = 0.237; P = 0.047), aspartate aminotransferase (AST; r = 0.389; P = 0.001) and alkaline phosphatase (r = -0.240; P = 0.043), and this was the only protein with significant differential expression when comparing patients with hepatocellular vs. cholestatic or mixed injury. In the longitudinal analysis, expression of 53 priority 1 proteins changed significantly from onset of DILI to 6-month follow-up, and nearly all proteins returned to expression levels comparable to control subjects. Ninety-two serum priority 1 proteins with significant differential expression were identified when comparing the DILI and control groups. Pattern analysis revealed proteins that are components of inflammation, immune system activation and several hepatotoxicity-specific pathways. Apolipoprotein E expression had the greatest power to differentiate DILI patients from controls (89% correct classification; AUROC = 0.97). Conclusion This proteomic analysis identified differentially expressed proteins that are components of pathways previously implicated in the pathogenesis of idiosyncratic drug-induced liver injury.

Original languageEnglish
Pages (from-to)600-612
Number of pages13
JournalAlimentary Pharmacology and Therapeutics
Volume35
Issue number5
DOIs
StatePublished - Mar 2012

Fingerprint

Chemical and Drug Induced Liver Injury
Proteomics
Serum
Proteins
Wounds and Injuries
Apolipoproteins E
Proteome
Aspartate Aminotransferases
Alanine Transaminase
Causality
Alkaline Phosphatase
Immune System
Mass Spectrometry
Inflammation

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Serum proteomic profiling in patients with drug-induced liver injury. / Bell, L. N.; Vuppalanchi, Raj; Watkins, P. B.; Bonkovsky, H. L.; Serrano, J.; Fontana, R. J.; Wang, Mu; Rochon, J.; Chalasani, Naga.

In: Alimentary Pharmacology and Therapeutics, Vol. 35, No. 5, 03.2012, p. 600-612.

Research output: Contribution to journalArticle

Bell, L. N. ; Vuppalanchi, Raj ; Watkins, P. B. ; Bonkovsky, H. L. ; Serrano, J. ; Fontana, R. J. ; Wang, Mu ; Rochon, J. ; Chalasani, Naga. / Serum proteomic profiling in patients with drug-induced liver injury. In: Alimentary Pharmacology and Therapeutics. 2012 ; Vol. 35, No. 5. pp. 600-612.
@article{6ae8f98270e143469aa406deb9a8abad,
title = "Serum proteomic profiling in patients with drug-induced liver injury",
abstract = "Background Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is difficult to predict, diagnose and treat. Aim To describe the global serum proteome of patients with DILI and controls. Methods A label-free, mass spectrometry-based quantitative proteomic approach was used to explore protein expression in serum samples from 74 DILI patients (collected within 14 days of DILI onset) and 40 controls. A longitudinal analysis was conducted in a subset of 21 DILI patients with available 6-month follow-up serum samples. Results Comparison of DILI patients based on pattern, severity and causality assessment of liver injury revealed many differentially expressed priority 1 proteins among groups. Expression of fumarylacetoacetase was correlated with alanine aminotransferase (ALT; r = 0.237; P = 0.047), aspartate aminotransferase (AST; r = 0.389; P = 0.001) and alkaline phosphatase (r = -0.240; P = 0.043), and this was the only protein with significant differential expression when comparing patients with hepatocellular vs. cholestatic or mixed injury. In the longitudinal analysis, expression of 53 priority 1 proteins changed significantly from onset of DILI to 6-month follow-up, and nearly all proteins returned to expression levels comparable to control subjects. Ninety-two serum priority 1 proteins with significant differential expression were identified when comparing the DILI and control groups. Pattern analysis revealed proteins that are components of inflammation, immune system activation and several hepatotoxicity-specific pathways. Apolipoprotein E expression had the greatest power to differentiate DILI patients from controls (89{\%} correct classification; AUROC = 0.97). Conclusion This proteomic analysis identified differentially expressed proteins that are components of pathways previously implicated in the pathogenesis of idiosyncratic drug-induced liver injury.",
author = "Bell, {L. N.} and Raj Vuppalanchi and Watkins, {P. B.} and Bonkovsky, {H. L.} and J. Serrano and Fontana, {R. J.} and Mu Wang and J. Rochon and Naga Chalasani",
year = "2012",
month = "3",
doi = "10.1111/j.1365-2036.2011.04982.x",
language = "English",
volume = "35",
pages = "600--612",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Serum proteomic profiling in patients with drug-induced liver injury

AU - Bell, L. N.

AU - Vuppalanchi, Raj

AU - Watkins, P. B.

AU - Bonkovsky, H. L.

AU - Serrano, J.

AU - Fontana, R. J.

AU - Wang, Mu

AU - Rochon, J.

AU - Chalasani, Naga

PY - 2012/3

Y1 - 2012/3

N2 - Background Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is difficult to predict, diagnose and treat. Aim To describe the global serum proteome of patients with DILI and controls. Methods A label-free, mass spectrometry-based quantitative proteomic approach was used to explore protein expression in serum samples from 74 DILI patients (collected within 14 days of DILI onset) and 40 controls. A longitudinal analysis was conducted in a subset of 21 DILI patients with available 6-month follow-up serum samples. Results Comparison of DILI patients based on pattern, severity and causality assessment of liver injury revealed many differentially expressed priority 1 proteins among groups. Expression of fumarylacetoacetase was correlated with alanine aminotransferase (ALT; r = 0.237; P = 0.047), aspartate aminotransferase (AST; r = 0.389; P = 0.001) and alkaline phosphatase (r = -0.240; P = 0.043), and this was the only protein with significant differential expression when comparing patients with hepatocellular vs. cholestatic or mixed injury. In the longitudinal analysis, expression of 53 priority 1 proteins changed significantly from onset of DILI to 6-month follow-up, and nearly all proteins returned to expression levels comparable to control subjects. Ninety-two serum priority 1 proteins with significant differential expression were identified when comparing the DILI and control groups. Pattern analysis revealed proteins that are components of inflammation, immune system activation and several hepatotoxicity-specific pathways. Apolipoprotein E expression had the greatest power to differentiate DILI patients from controls (89% correct classification; AUROC = 0.97). Conclusion This proteomic analysis identified differentially expressed proteins that are components of pathways previously implicated in the pathogenesis of idiosyncratic drug-induced liver injury.

AB - Background Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is difficult to predict, diagnose and treat. Aim To describe the global serum proteome of patients with DILI and controls. Methods A label-free, mass spectrometry-based quantitative proteomic approach was used to explore protein expression in serum samples from 74 DILI patients (collected within 14 days of DILI onset) and 40 controls. A longitudinal analysis was conducted in a subset of 21 DILI patients with available 6-month follow-up serum samples. Results Comparison of DILI patients based on pattern, severity and causality assessment of liver injury revealed many differentially expressed priority 1 proteins among groups. Expression of fumarylacetoacetase was correlated with alanine aminotransferase (ALT; r = 0.237; P = 0.047), aspartate aminotransferase (AST; r = 0.389; P = 0.001) and alkaline phosphatase (r = -0.240; P = 0.043), and this was the only protein with significant differential expression when comparing patients with hepatocellular vs. cholestatic or mixed injury. In the longitudinal analysis, expression of 53 priority 1 proteins changed significantly from onset of DILI to 6-month follow-up, and nearly all proteins returned to expression levels comparable to control subjects. Ninety-two serum priority 1 proteins with significant differential expression were identified when comparing the DILI and control groups. Pattern analysis revealed proteins that are components of inflammation, immune system activation and several hepatotoxicity-specific pathways. Apolipoprotein E expression had the greatest power to differentiate DILI patients from controls (89% correct classification; AUROC = 0.97). Conclusion This proteomic analysis identified differentially expressed proteins that are components of pathways previously implicated in the pathogenesis of idiosyncratic drug-induced liver injury.

UR - http://www.scopus.com/inward/record.url?scp=84862777266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777266&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2011.04982.x

DO - 10.1111/j.1365-2036.2011.04982.x

M3 - Article

C2 - 22403816

AN - SCOPUS:84862777266

VL - 35

SP - 600

EP - 612

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -